We use cookies on this website to enhance your browser experience. By continuing to use this site, you are providing us with your consent to our use of cookies on the site. To learn more about cookies and how we use them, please review our privacy policy.

Stuart M. Gerson, a Member of the Firm in the Litigation and Health Care & Life Sciences practices, in the firm's Washington, DC, and New York offices, was quoted in Law360, in “Obama's FDA Leaves Mark with Last-Minute Policy Blitz,” by Jeff Overley. (Read the full version – subscription required.)

Following is an excerpt:

“This is a war between two administrations' views,” Epstein Becker Green member Stuart M. Gerson said. “The reason that ... there's so much of it happening now is to get as much of this on the record as they can, in the hopes that as little of it as possible will be overridden or repealed in the new administration.” …

“These are policies and judgments that the Democratic administration, the Democratic leadership of these agencies, wants to enact. They believe it's the right thing to do,” Gerson said. “But they are equally conscious of the fact that if the field were clear, that their successors would act in a different way.”